3 completed, 1 recruiting, 1 unknown. 5 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Recruiting 1, Unknown 1 |
| Phase 2 | 2 | Recruiting 1, Unknown 1 |
Follow Jaundice, Neonatal: new trials by email Literature Review of Jaundice, Neonatal trials Research Report on Jaundice, Neonatal
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Newborn Jaundice - An Investigation of Different Approaches to Light Therapy Continuous Phototherapy with a irradiance of 40 µW/cm2/nm from the overhead light, Continuos Phototherapy with a irradiance of 55 µW/cm2/nm from the overhead light, Continuous Phototherapy with a irradiance of 70 µW/cm2/nm from the overhead light - Neonatal Hyperbilirubinemia | Phase 2 / Phase 3 | Recruiting | Regionshospital Nordjylland | 116 | 2025-01-14 | 2025-11-20 |
| Comparison of Effects of Fenofibrate Adjuvant Therapy Versus Conventional Phototherapy in Neonatal Jaundice. Fenofibrate, Phototherapy - Physiological Neonatal Jaundice, Physiological Hyperbilirubinaemia | Phase 2 / Phase 3 | Unknown | Muhammad Zark | 156 | 2024-04-01 | 2024-04-04 |
| Role of Oral Zinc in Reducing Neonatal Indirect Hyperbilirubinemia Oral zinc sulfate and standard phototherapy - Neonatal Jaundice | Phase 3 | Completed | National Liver Institute, Egypt | 192 | 2018-06-01 | 2024-01-29 |
| Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight Aggressive Phototherapy 501-750g, Aggressive Phototherapy 751-1000g, Conservative Phototherapy 501-750g - Hyperbilirubinemia, Neonatal, Jaundice, Neonatal | Phase 3 | Completed | NICHD Neonatal Research Network | 1974 | 2002-09-01 | 2019-03-22 |
| Efficacy and Safety of Stannsoporfin in Neonates stannsoporfin, Sham Injection - Nutritional and Metabolic Diseases | Phase 3 | Completed | InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company | 185 | 2002-05-01 | 2019-10-29 |
Hyperbilirubinemia (2) · Hyperbilirubinemia, Neonatal (2) · Kernicterus (1) · Nutritional and Metabolic Diseases (1) · Premature Birth (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Infant, Newborn, Diseases (5) · Pathologic Processes (5) · Pathological Conditions, Signs and Symptoms (5) · Hyperbilirubinemia (3) · Hyperbilirubinemia, Neonatal (3) · Brain Diseases (1) · Brain Diseases, Metabolic (1) · Central Nervous System Diseases (1) · Erythroblastosis, Fetal (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Metabolic Diseases (1)
Fenofibrate (1) · Phototherapy (1) · Zinc Sulfate (1) · salicylhydroxamic acid (1) · tin mesoporphyrin (1)
InfaCare Pharmaceuticals Corporation, a Mallinckrodt Company (1) · Muhammad Zark (1) · NICHD Neonatal Research Network (1) · National Liver Institute, Egypt (1) · Regionshospital Nordjylland (1)
United States (2) · Denmark (1) · Egypt (1) · Pakistan (1)
Abbot R. Laptook, MD (1) · Abhik Das, PhD (1) · Barbara J. Stoll, MD (1) · Brenda B. Poindexter, MD MS (1) · Brenda H. Morris, MD (1) · Hala H. Elsaeed, professor (1) · Hanaa A. El- Alraby (1) · Heba S. Sallam, specialist (1) · Krisa P. Van Meurs, MD (1) · Kurt Schibler, MD (1) · Michele C. Walsh, MD MS (1) · Mohsen H Hussein, professor (1) · Neil N. Finer, MD (1) · Pablo J. Sanchez, MD (1)
PMID 17069786, PMID 17974745, PMID 18971491, PMID 20105142
M01RR000030 (1), M01RR000032 (1), M01RR000039 (1), M01RR000044 (1), M01RR000070 (1), M01RR000080 (1), M01RR000633 (1), M01RR000750 (1), M01RR006022 (1), M01RR007122 (1), M01RR008084 (1), M01RR016587 (1), U01HD036790 (1), U10HD021364 (1), U10HD021373 (1)